These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 17822184)
1. Differential properties of enantiomers of commercially available racemates. Gulati V J Indian Med Assoc; 2007 Apr; 105(4):173-4, 176. PubMed ID: 17822184 [TBL] [Abstract][Full Text] [Related]
2. The future lies in chiral purity: a perspective. Gurjar MK J Indian Med Assoc; 2007 Apr; 105(4):177-8. PubMed ID: 17822185 [TBL] [Abstract][Full Text] [Related]
3. [Chiral switch: pure enantiomers of drugs instead of racemic mixtures]. Valentová J; Hutt AJ Ceska Slov Farm; 2004 Nov; 53(6):285-93. PubMed ID: 15630994 [TBL] [Abstract][Full Text] [Related]
4. Chirality and its implications in transdermal drug development. Reddy IK; Kommuru TR; Zaghloul AA; Khan MA Crit Rev Ther Drug Carrier Syst; 2000; 17(4):285-325. PubMed ID: 10958245 [TBL] [Abstract][Full Text] [Related]
6. [The effect of chirality in clinical pharmacology]. Le Corre P; Sado P; Le Verge R J Pharm Belg; 1991; 46(5):331-47. PubMed ID: 1791526 [TBL] [Abstract][Full Text] [Related]
7. Enantiomers: implications and complications in developmental pharmacology. Eichelbaum M Dev Pharmacol Ther; 1992; 18(3-4):131-4. PubMed ID: 1306801 [TBL] [Abstract][Full Text] [Related]
8. Biological significance of the enantiomeric purity of drugs. Waldeck B Chirality; 1993; 5(5):350-5. PubMed ID: 8398592 [TBL] [Abstract][Full Text] [Related]
9. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds. Calcaterra A; D'Acquarica I J Pharm Biomed Anal; 2018 Jan; 147():323-340. PubMed ID: 28942107 [TBL] [Abstract][Full Text] [Related]
10. [Stereochemistry--an overlooked problem in medical treatment and research]. Mikkelsen EO Ugeskr Laeger; 1990 Jul; 152(28):2029-32. PubMed ID: 2195737 [TBL] [Abstract][Full Text] [Related]
11. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States. Miller CP; Ullrich JW Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591 [TBL] [Abstract][Full Text] [Related]
12. [Chiral compounds and their pharmacologic effects]. Slováková A; Hutt AJ Ceska Slov Farm; 1999 May; 48(3):107-12. PubMed ID: 10422348 [TBL] [Abstract][Full Text] [Related]
13. [Chirality and drugs]. Testa B; Reist M; Carrupt PA Ann Pharm Fr; 2000 Jul; 58(4):239-46. PubMed ID: 10915971 [TBL] [Abstract][Full Text] [Related]
14. Chiral Aspects of Local Anesthetics. Čižmáriková R; Čižmárik J; Valentová J; Habala L; Markuliak M Molecules; 2020 Jun; 25(12):. PubMed ID: 32545678 [TBL] [Abstract][Full Text] [Related]
15. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Brocks DR Biopharm Drug Dispos; 2006 Nov; 27(8):387-406. PubMed ID: 16944450 [TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetic implications associated to the use of drugs as racemates or pure enantiomers]. Speisky H; Squella JA; Nuñez-Vergara LJ Rev Med Chil; 1995 Jul; 123(7):884-91. PubMed ID: 8560121 [TBL] [Abstract][Full Text] [Related]
18. The FDA perspective on the development of stereoisomers. De Camp WH Chirality; 1989; 1(1):2-6. PubMed ID: 2642032 [TBL] [Abstract][Full Text] [Related]
19. Discovery of a solid solution of enantiomers in a racemate-forming system by seeding. Huang J; Chen S; Guzei IA; Yu L J Am Chem Soc; 2006 Sep; 128(36):11985-92. PubMed ID: 16953640 [TBL] [Abstract][Full Text] [Related]